HH
Harte Hanks, Inc.
HHS · NASDAQ
$4.22 +1.44% (+$0.06)
1M +69.48%
Market Cap $31.3M
P/E Ratio -
Div. Yield -
ROE 30.13%
Bulios Fair Price
$5.58
32.2% upside
Current Price
$4.22
Undervalued Fair Value Overvalued
According to Bulios Fair Price, HHS is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
94 /100
Cheap P/S 0.20x
P/B 2.04x
P/E N/A
Growth
9 /100
Declining Rev. growth 8.20%
Book val. growth 2.96%
EPS growth N/A
Profitability
7 /100
Weak Gross margin 22.72%
FCF margin 0.94%
Net margin 3.70%
Quality
15 /100
Poor ROIC 6.31%
Asset turnover 1.76x
ROE 30.13%
Debt
28 /100
High Debt/Equity 1.57x
Int. coverage -19.03x
Current ratio 1.30x
Stability
43 /100
Moderate Beta -0.04x
Profitable years 0
Rev. volatility 5.36%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about HHS
Online
Sector
Industrials
Industry
Specialty Business Services
CEO
David Fisher
Employees
1,719
Headquarters
Chelmsford
Upcoming events
05 NOV
Earnings
Upcoming earnings report